January 2012 Newsletter

January 25, 2012:

Premium IOLs Drove 2011 IOL Market

2011 demand for premium IOLs spurred growth in the global IOL market, while commercialization of the first laser refractive cataract surgery systems resulted in more units sold, more surgeons trained, and more procedures performed than we earlier forecast.

January 25, 2012:

2011 Refractive Surgery Market Buffeted by Economic Winds

2011 saw global growth in the refractive surgery market driven by emerging economies, as markets in wealthy nations experienced more tentative gains (US) or lost momentum (Europe).

January 25, 2012:

2011 IVT Injections Climbed as Waits for CATT Data and Eylea’s Launch Built Anticipation of Market Shifts

In 2011, IVT injections continued to climb and retinal surgeons increasingly used micro-incision surgical techniques and instruments. All the while anticipation built first for CATT results then for Eylea’s eagerly awaited market entry.

January 25, 2012:

Ophthalmic Ventures Raise Nearly $350 Million for New Product Development in 2011

In 2011, nearly $350 million in venture capital funded ophthalmic development projects.

January 25, 2012:

FDA Approves Key Ophthalmic Devices in 2011

Three new ophthalmic devices gained FDA regulatory approval in 2011 and many important 501(k) clearances were granted.

January 25, 2012:

Only One New Ophthalmic Drug Gets a 2011 FDA Nod

Only one new ophthalmic pharmaceutical received FDA approval, while approvals were also granted to several generics.

January 25, 2012:

January 2012 News Briefs

This month's news includes the latest from Regeneron Pharmaceuticals, Genentech/Roche, Avedro, and Thrombogenics.

Social media